Efficacy and Safety Trial of ADU-S100 and Pembrolizumab in Head and Neck Cancer
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03937141 |
Recruitment Status :
Terminated
(No substantial anti-tumor activity was observed.)
First Posted : May 3, 2019
Results First Posted : January 3, 2022
Last Update Posted : January 3, 2022
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Metastatic Head and Neck Cancer Recurrent Head and Neck Cancer | Drug: ADU-S100 | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 16 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Phase 2 Efficacy and Safety Trial of ADU-S100 and Pembrolizumab in Adults With Head and Neck Cancer |
Actual Study Start Date : | August 26, 2019 |
Actual Primary Completion Date : | May 10, 2021 |
Actual Study Completion Date : | June 10, 2021 |
Arm | Intervention/treatment |
---|---|
Experimental: ADU-S100 and pembrolizumab
All eligible subjects will receive intravenous (IV) infusions of pembrolizumab and intratumoral injections of ADU-S100.
|
Drug: ADU-S100
intratumoral
Other Name: MIW815 |
- Evaluation of Clinical Activity by the Objective Response Rate (ORR; Complete Response [CR] and Partial Response [PR]) Per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 [ Time Frame: Up to 25 months ]To determine ORR of ADU-S100 in combination with pembrolizumab in subjects with recurrent or metastatic head and neck squamous cell cancer (HNSCC). ORR is defined as the percentage of subjects with evidence of a confirmed complete response (CR) or partial response (PR) as per Response Evaluation Criteria In Solid Tumors (RECIST) Version 1.1 and as assessed by the investigator.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Histological or cytological confirmation of recurrent or metastatic HNSCC
- Measurable disease as defined by RECIST v1.1
- PD-L1 positive
Exclusion Criteria:
- Diagnosis of recurrent or metastatic carcinoma of the nasopharynx, squamous cell carcinoma of unknown primary histology; or salivary gland or non-squamous histologies (e.g. mucosal melanoma)
- Disease amenable to local therapy with curative intent (surgery or radiation therapy with or without chemotherapy)
- Prior systemic anti-cancer therapy (use of chemotherapeutic agents, targeted small molecules, immunotherapy, or monoclonal antibodies) for the treatment of recurrent or metastatic HNSCC
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03937141
Documents provided by Chinook Therapeutics, Inc. ( Chinook Therapeutics, Inc. (formerly Aduro) ):
Responsible Party: | Chinook Therapeutics, Inc. (formerly Aduro) |
ClinicalTrials.gov Identifier: | NCT03937141 |
Other Study ID Numbers: |
ADU-CL-20 |
First Posted: | May 3, 2019 Key Record Dates |
Results First Posted: | January 3, 2022 |
Last Update Posted: | January 3, 2022 |
Last Verified: | December 2021 |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Head and Neck Neoplasms Neoplasms by Site Neoplasms |